In This Article:
As of March 2025, the U.S. stock market has been grappling with volatility, highlighted by recent declines following the announcement of new tariffs on automobile imports. Despite these broader market challenges, penny stocks remain an intriguing investment avenue for those seeking opportunities in smaller or newer companies. While often seen as a relic from past eras, penny stocks can offer significant growth potential when backed by strong financial health and sound fundamentals.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
Safe Bulkers (NYSE:SB) | $3.76 | $392.12M | ★★★★☆☆ |
Tuya (NYSE:TUYA) | $3.43 | $1.98B | ★★★★★★ |
Cango (NYSE:CANG) | $4.01 | $411.2M | ★★★★★★ |
Sensus Healthcare (NasdaqCM:SRTS) | $4.69 | $76.54M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
TETRA Technologies (NYSE:TTI) | $3.75 | $467.35M | ★★★★☆☆ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.55 | $76.44M | ★★★★★★ |
BAB (OTCPK:BABB) | $0.83 | $5.75M | ★★★★★★ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $153.34M | ★★★★★★ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.7966 | $76.45M | ★★★★★☆ |
Click here to see the full list of 772 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
OmniAb
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, to aid in the discovery of therapeutics across the United States, Europe, Japan, China, and Canada; it has a market cap of $296.79 million.
Operations: The company's revenue segment is derived from Research Services, amounting to $26.39 million.
Market Cap: $296.79M
OmniAb, Inc., a biotechnology company with a market cap of US$296.79 million, has shown volatility typical of penny stocks. Despite being debt-free and having short-term assets of US$68.1 million that exceed liabilities, OmniAb remains unprofitable with increasing losses over the past five years. Recent earnings reported a net loss for 2024 at US$62.03 million on revenues of US$26.39 million, down from the previous year. The company's revenue is forecast to grow by 27% annually but profitability isn't expected in the near term. Strategic alliances like the one with Chiome Bioscience aim to enhance technology synergies and potential future profitability without immediate financial impact.
-
Unlock comprehensive insights into our analysis of OmniAb stock in this financial health report.
-
Assess OmniAb's future earnings estimates with our detailed growth reports.
Zhihu
Simply Wall St Financial Health Rating: ★★★★★☆